These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19528132)

  • 1. Model calibration in the continual reassessment method.
    Lee SM; Ying Kuen Cheung
    Clin Trials; 2009 Jun; 6(3):227-38. PubMed ID: 19528132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calibration of prior variance in the Bayesian continual reassessment method.
    Lee SM; Cheung YK
    Stat Med; 2011 Jul; 30(17):2081-9. PubMed ID: 21413054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of the initial design for the two-stage continual reassessment method.
    Jia X; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):495-506. PubMed ID: 28300466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust EM Continual Reassessment Method in Oncology Dose Finding.
    Yuan Y; Yin G
    J Am Stat Assoc; 2011 Sep; 106(495):818-831. PubMed ID: 22375092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
    Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
    Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of irrational dose assignment definitions using the continual reassessment method.
    Wages NA; Bagley E
    Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simulation-free approach to assessing the performance of the continual reassessment method.
    Braun TM
    Stat Med; 2020 Dec; 39(30):4651-4666. PubMed ID: 32939800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.